(335) Endoscopic Delivery of Regorafenib-Curcumin Microparticles to Locally Treat Colorectal Cancer

Introduction: Colorectal cancer (CRC) is the second most fatal cancer with treatments including intravenous and oral therapies like regorafenib(1). However, these therapies are non-specific and lead to systemic effects including severe hepatoxicity and hypertension(1,2). As a result, there is an unmet need for improved CRC treatments with limited adverse effects. We aim to utilize the anti-cancer effects of curcumin to reinforce the anti-cancer activity of regorafenib by fabricating drug-curcumin particles for endoscopic delivery that can increase local drug concentration and minimize systemic effects.